• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia.澳大利亚异基因造血干细胞移植存活患者补充和替代医学疗法使用情况的流行病学研究
Cancer Med. 2016 Dec;5(12):3606-3614. doi: 10.1002/cam4.889. Epub 2016 Oct 27.
2
Predictors of post traumatic growth in allogeneic hematopoietic stem cell transplantation survivors: a cross-sectional survey.异基因造血干细胞移植幸存者创伤后成长的预测因素:一项横断面调查。
BMC Psychol. 2023 Aug 16;11(1):235. doi: 10.1186/s40359-023-01204-4.
3
Nutritional Supplements and Complementary/Alternative Medications in Patients With Hematologic Diseases and Hematopoietic Stem Cell Transplantation.血液系统疾病和造血干细胞移植患者的营养补充剂和补充/替代药物。
Transplant Cell Ther. 2021 Jun;27(6):467-473. doi: 10.1016/j.jtct.2021.03.011. Epub 2021 Mar 14.
4
A survey of infectious diseases and vaccination uptake in long-term hematopoietic stem cell transplant survivors in Australia.澳大利亚长期造血干细胞移植幸存者的传染病及疫苗接种情况调查。
Transpl Infect Dis. 2019 Apr;21(2):e13043. doi: 10.1111/tid.13043. Epub 2019 Jan 16.
5
The experiences of persons living with HIV who participate in mind-body and energy therapies: a systematic review protocol of qualitative evidence.参与身心与能量疗法的艾滋病病毒感染者的经历:定性证据的系统评价方案
JBI Database System Rev Implement Rep. 2015 Oct;13(10):41-9. doi: 10.11124/jbisrir-2015-2321.
6
Health status, late effects and long-term survivorship of allogeneic bone marrow transplantation: a retrospective study.异基因骨髓移植的健康状况、远期效应及长期生存情况:一项回顾性研究。
Intern Med J. 2014 Feb;44(2):139-47. doi: 10.1111/imj.12336.
7
A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties.造血干细胞移植幸存者中补充/替代医学应用的观点:益处和不确定性。
Cancer. 2015 Jul 15;121(14):2303-13. doi: 10.1002/cncr.29382. Epub 2015 Apr 14.
8
Complementary and alternative medicine (CAM) among hospitalised patients: reported use of CAM and reasons for use, CAM preferred during hospitalisation, and the socio-demographic determinants of CAM users.住院患者中的补充和替代医学(CAM):CAM 的报告使用情况和使用原因、住院期间首选的 CAM 以及 CAM 用户的社会人口学决定因素。
Complement Ther Clin Pract. 2011 Nov;17(4):199-205. doi: 10.1016/j.ctcp.2011.05.001. Epub 2011 Jun 25.
9
Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后幸存者的晚期并发症和生活质量评估。
Support Care Cancer. 2021 Feb;29(2):975-986. doi: 10.1007/s00520-020-05572-0. Epub 2020 Jun 17.
10
Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT).澳大利亚异基因造血干细胞移植(BMT)幸存者对癌症筛查指南的依从性。
Cancer Med. 2016 Jul;5(7):1702-16. doi: 10.1002/cam4.729. Epub 2016 Apr 25.

引用本文的文献

1
Decisional Regret in Long-Term Australian Allogeneic Hematopoietic Stem Cell Transplantation Survivors: A Cross-Sectional Survey.长期澳大利亚异基因造血干细胞移植幸存者的决策后悔:一项横断面调查。
Clin Nurs Res. 2023 Nov;32(8):1134-1144. doi: 10.1177/10547738231180337. Epub 2023 Jun 16.
2
Long-term treatment burden following allogeneic blood and marrow transplantation in NSW, Australia: a cross-sectional survey.澳大利亚新南威尔士州异基因血液和骨髓移植后的长期治疗负担:一项横断面调查。
J Cancer Surviv. 2022 Apr;16(2):432-444. doi: 10.1007/s11764-021-01038-2. Epub 2021 Apr 4.

本文引用的文献

1
A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties.造血干细胞移植幸存者中补充/替代医学应用的观点:益处和不确定性。
Cancer. 2015 Jul 15;121(14):2303-13. doi: 10.1002/cncr.29382. Epub 2015 Apr 14.
2
Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment.接受化疗的老年癌症患者的多重用药及潜在不适当用药:对治疗期间化疗相关毒性和住院情况的影响。
J Am Geriatr Soc. 2014 Aug;62(8):1505-12. doi: 10.1111/jgs.12942. Epub 2014 Jul 15.
3
Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update.异基因造血干细胞移植后的长期并发症和副作用:最新进展。
Blood Cancer J. 2011 Apr;1(4):e16. doi: 10.1038/bcj.2011.14. Epub 2011 Apr 29.
4
Resilience in children undergoing stem cell transplantation: results of a complementary intervention trial.儿童干细胞移植中的韧性:一项补充干预试验的结果。
Pediatrics. 2012 Mar;129(3):e762-70. doi: 10.1542/peds.2011-1816. Epub 2012 Feb 6.
5
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.造血细胞移植后长期生存者的推荐筛查和预防措施。
Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71. doi: 10.1016/j.bbmt.2011.12.519. Epub 2011 Dec 13.
6
How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis.有多少癌症患者使用补充和替代医学:系统评价和荟萃分析。
Integr Cancer Ther. 2012 Sep;11(3):187-203. doi: 10.1177/1534735411423920. Epub 2011 Oct 21.
7
Use of complementary therapies by individuals with or at risk for cardiovascular disease: results of the 2007 National Health Interview Survey.有或有心血管疾病风险的个人使用补充疗法:2007 年全国健康访谈调查结果。
J Cardiovasc Nurs. 2012 Mar-Apr;27(2):96-102. doi: 10.1097/JCN.0b013e31821888cd.
8
How I treat late effects in adults after allogeneic stem cell transplantation.成人异基因造血干细胞移植后晚期效应的治疗策略
Blood. 2011 Mar 17;117(11):3002-9. doi: 10.1182/blood-2010-10-263095. Epub 2010 Dec 30.
9
Prevalence of complementary and alternative medicine use in cancer patients during treatment.癌症患者在治疗期间使用补充和替代医学的患病率。
Support Care Cancer. 2005 Oct;13(10):806-11. doi: 10.1007/s00520-004-0770-7. Epub 2005 Feb 15.
10
Potential health risks of complementary alternative medicines in cancer patients.癌症患者使用补充替代医学的潜在健康风险。
Br J Cancer. 2004 Jan 26;90(2):408-13. doi: 10.1038/sj.bjc.6601560.

澳大利亚异基因造血干细胞移植存活患者补充和替代医学疗法使用情况的流行病学研究

Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia.

作者信息

Lindsay Julian, Kabir Masrura, Gilroy Nicole, Dyer Gemma, Brice Lisa, Moore John, Greenwood Matthew, Hertzberg Mark, Gottlieb David, Larsen Stephen R, Hogg Megan, Brown Louisa, Huang Gillian, Tan Jeff, Ward Christopher, Kerridge Ian

机构信息

Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Westmead Hospital, Sydney, New South Wales, Australia.

出版信息

Cancer Med. 2016 Dec;5(12):3606-3614. doi: 10.1002/cam4.889. Epub 2016 Oct 27.

DOI:10.1002/cam4.889
PMID:27790858
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5224858/
Abstract

In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adults who had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012. Participants completed a 402-item questionnaire regarding the use of CAM, medical complications, specialist referrals, medications and therapies, infections, vaccinations, cancer screening, lifestyle, and occupational issues and relationship status following stem cell transplantation. A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. Of 432 participants who returned the completed survey (66% of total eligible, 76% of those contacted), 239 (54.1%) HSCT survivors used at least one form of CAM. These included dietary modification (13.6%), vitamin therapy (30%), spiritual or mind-body therapy (17.2%), herbal supplements (13.5%), manipulative and body-based therapies (26%), Chinese medicine (3.5%), reiki (3%), and homeopathy (3%). These results definitively demonstrate that a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population.

摘要

除了使用处方常规药物外,许多异基因造血干细胞移植(HSCT)幸存者还使用补充和替代医学疗法(CAM),然而,异基因HSCT幸存者使用CAM的频率和类型仍不清楚。研究参与者为2000年1月1日至2012年12月31日期间接受异基因HSCT的成年人。参与者完成了一份包含402个项目的问卷,内容涉及CAM的使用、医学并发症、专科转诊、药物和治疗、感染、疫苗接种、癌症筛查、生活方式、职业问题以及干细胞移植后的关系状况。在研究期间共进行了1475例异基因HSCT。在研究抽样时已知存活的669名接受者中,有583名可以联系上并收到了研究包。在432名返回完整调查问卷的参与者中(占总合格人数的66%,占被联系者的76%),239名(54.1%)HSCT幸存者至少使用了一种形式的CAM。这些包括饮食调整(13.6%)、维生素疗法(30%)、精神或身心疗法(17.2%)、草药补充剂(13.5%)、手法和身体疗法(26%)、中药(3.5%)、灵气疗法(3%)和顺势疗法(3%)。这些结果明确表明,很大一部分HSCT幸存者正在使用一种或多种形式的CAM疗法。鉴于针对该患者群体的特定CAM疗法的小型研究显示出潜在益处,以及有明确记录显示某些疗法无益处甚至有毒性,这一结果表明,对于进一步研究以确定CAM疗法在这一不断增长的人群中的疗效和安全性,存在很大的未满足需求。